Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development review-article

Hoai J. Hallam, Steven Hallam, Sergio Rodriguez, Alan Barrett, David Beasley, Arlene Chua, Thomas Ksiazek, Gregg Milligan, Vaseeharan Sathiyamoorthy, Lisa M. Reece

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Lassa fever (LF) is a zoonotic disease associated with acute and potentially fatal hemorrhagic illness caused by the Lassa virus (LASV), a member of the family Arenaviridae. It is generally assumed that a single infection with LASV will produce life-long protective immunity. This suggests that protective immunity induced by vaccination is an achievable goal and that cell-mediated immunity may play a more important role in protection, at least following natural infection. Seropositive individuals in endemic regions have been shown to have LASV-specific T cells recognizing epitopes for nucleocapsid protein (NP) and glycoprotein precursor (GPC), suggesting that these will be important vaccine immunogens. The role of neutralizing antibodies in protective immunity is still equivocal as recent studies suggest a role for neutralizing antibodies. There is extensive genetic heterogeneity among LASV strains that is of concern in the development of assays to detect and identify all four LASV lineages. Furthermore, the gene disparity may complicate the synthesis of effective vaccines that will provide protection across multiple lineages. Non-human primate models of LASV infection are considered the gold standard for recapitulation of human LF. The most promising vaccine candidates to date are the ML29 (a live attenuated reassortant of Mopeia and LASV), vesicular stomatitis virus (VSV) and vaccinia-vectored platforms based on their ability to induce protection following single doses, high rates of survival following challenge, and the use of live virus platforms. To date no LASV vaccine candidates have undergone clinical evaluation.

Original languageEnglish (US)
Article number11
Journalnpj Vaccines
Volume3
Issue number1
DOIs
StatePublished - Dec 1 2018

Fingerprint

Lassa Fever
Lassa virus
Virology
Epidemiology
Vaccines
Research
Immunity
Neutralizing Antibodies
Arenaviridae
Reassortant Viruses
Nucleocapsid Proteins
Vesicular Stomatitis
Aptitude
T-Lymphocyte Epitopes
Protein Precursors
Genetic Heterogeneity
Vaccinia virus
Zoonoses
Virus Diseases
Infection

ASJC Scopus subject areas

  • Pharmacology
  • Infectious Diseases
  • Immunology
  • Pharmacology (medical)

Cite this

Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development review-article. / Hallam, Hoai J.; Hallam, Steven; Rodriguez, Sergio; Barrett, Alan; Beasley, David; Chua, Arlene; Ksiazek, Thomas; Milligan, Gregg; Sathiyamoorthy, Vaseeharan; Reece, Lisa M.

In: npj Vaccines, Vol. 3, No. 1, 11, 01.12.2018.

Research output: Contribution to journalArticle

Hallam, Hoai J. ; Hallam, Steven ; Rodriguez, Sergio ; Barrett, Alan ; Beasley, David ; Chua, Arlene ; Ksiazek, Thomas ; Milligan, Gregg ; Sathiyamoorthy, Vaseeharan ; Reece, Lisa M. / Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development review-article. In: npj Vaccines. 2018 ; Vol. 3, No. 1.
@article{4c795b3624434f7fb59b889c5b823d00,
title = "Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development review-article",
abstract = "Lassa fever (LF) is a zoonotic disease associated with acute and potentially fatal hemorrhagic illness caused by the Lassa virus (LASV), a member of the family Arenaviridae. It is generally assumed that a single infection with LASV will produce life-long protective immunity. This suggests that protective immunity induced by vaccination is an achievable goal and that cell-mediated immunity may play a more important role in protection, at least following natural infection. Seropositive individuals in endemic regions have been shown to have LASV-specific T cells recognizing epitopes for nucleocapsid protein (NP) and glycoprotein precursor (GPC), suggesting that these will be important vaccine immunogens. The role of neutralizing antibodies in protective immunity is still equivocal as recent studies suggest a role for neutralizing antibodies. There is extensive genetic heterogeneity among LASV strains that is of concern in the development of assays to detect and identify all four LASV lineages. Furthermore, the gene disparity may complicate the synthesis of effective vaccines that will provide protection across multiple lineages. Non-human primate models of LASV infection are considered the gold standard for recapitulation of human LF. The most promising vaccine candidates to date are the ML29 (a live attenuated reassortant of Mopeia and LASV), vesicular stomatitis virus (VSV) and vaccinia-vectored platforms based on their ability to induce protection following single doses, high rates of survival following challenge, and the use of live virus platforms. To date no LASV vaccine candidates have undergone clinical evaluation.",
author = "Hallam, {Hoai J.} and Steven Hallam and Sergio Rodriguez and Alan Barrett and David Beasley and Arlene Chua and Thomas Ksiazek and Gregg Milligan and Vaseeharan Sathiyamoorthy and Reece, {Lisa M.}",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41541-018-0049-5",
language = "English (US)",
volume = "3",
journal = "npj Vaccines",
issn = "2059-0105",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development review-article

AU - Hallam, Hoai J.

AU - Hallam, Steven

AU - Rodriguez, Sergio

AU - Barrett, Alan

AU - Beasley, David

AU - Chua, Arlene

AU - Ksiazek, Thomas

AU - Milligan, Gregg

AU - Sathiyamoorthy, Vaseeharan

AU - Reece, Lisa M.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Lassa fever (LF) is a zoonotic disease associated with acute and potentially fatal hemorrhagic illness caused by the Lassa virus (LASV), a member of the family Arenaviridae. It is generally assumed that a single infection with LASV will produce life-long protective immunity. This suggests that protective immunity induced by vaccination is an achievable goal and that cell-mediated immunity may play a more important role in protection, at least following natural infection. Seropositive individuals in endemic regions have been shown to have LASV-specific T cells recognizing epitopes for nucleocapsid protein (NP) and glycoprotein precursor (GPC), suggesting that these will be important vaccine immunogens. The role of neutralizing antibodies in protective immunity is still equivocal as recent studies suggest a role for neutralizing antibodies. There is extensive genetic heterogeneity among LASV strains that is of concern in the development of assays to detect and identify all four LASV lineages. Furthermore, the gene disparity may complicate the synthesis of effective vaccines that will provide protection across multiple lineages. Non-human primate models of LASV infection are considered the gold standard for recapitulation of human LF. The most promising vaccine candidates to date are the ML29 (a live attenuated reassortant of Mopeia and LASV), vesicular stomatitis virus (VSV) and vaccinia-vectored platforms based on their ability to induce protection following single doses, high rates of survival following challenge, and the use of live virus platforms. To date no LASV vaccine candidates have undergone clinical evaluation.

AB - Lassa fever (LF) is a zoonotic disease associated with acute and potentially fatal hemorrhagic illness caused by the Lassa virus (LASV), a member of the family Arenaviridae. It is generally assumed that a single infection with LASV will produce life-long protective immunity. This suggests that protective immunity induced by vaccination is an achievable goal and that cell-mediated immunity may play a more important role in protection, at least following natural infection. Seropositive individuals in endemic regions have been shown to have LASV-specific T cells recognizing epitopes for nucleocapsid protein (NP) and glycoprotein precursor (GPC), suggesting that these will be important vaccine immunogens. The role of neutralizing antibodies in protective immunity is still equivocal as recent studies suggest a role for neutralizing antibodies. There is extensive genetic heterogeneity among LASV strains that is of concern in the development of assays to detect and identify all four LASV lineages. Furthermore, the gene disparity may complicate the synthesis of effective vaccines that will provide protection across multiple lineages. Non-human primate models of LASV infection are considered the gold standard for recapitulation of human LF. The most promising vaccine candidates to date are the ML29 (a live attenuated reassortant of Mopeia and LASV), vesicular stomatitis virus (VSV) and vaccinia-vectored platforms based on their ability to induce protection following single doses, high rates of survival following challenge, and the use of live virus platforms. To date no LASV vaccine candidates have undergone clinical evaluation.

UR - http://www.scopus.com/inward/record.url?scp=85044461072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044461072&partnerID=8YFLogxK

U2 - 10.1038/s41541-018-0049-5

DO - 10.1038/s41541-018-0049-5

M3 - Article

AN - SCOPUS:85044461072

VL - 3

JO - npj Vaccines

JF - npj Vaccines

SN - 2059-0105

IS - 1

M1 - 11

ER -